SCHEMBL3661640

SCHEMBL3661640

NC(=O)c1cccc(NC(=O)c2ccccc2Oc2ccc(F)cc2)c1

nearest known ligand 0.61

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ SCN8A Q9UQD0 2/20 0.61
▸ SCN10A Q9Y5Y9 2/20 0.61
▸ PNLIP P16233 1/20 0.57
▸ MEN1 O00255 2/20 0.56
▸ KMT2A Q03164 2/20 0.56
▸ RXFP1 Q9HBX9 1/20 0.53
▸ KCNK3 O14649 2/20 0.51
▸ KCNK9 Q9NPC2 2/20 0.51
▸ KDM4E B2RXH2 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13894164 0.91 RXFP1 (0.58) MEN1KMT2ARXFP1KCNK3KCNK9
SCHEMBL13852930 0.89 PARP1 (0.53) SCN8ASCN10APNLIPMEN1KMT2A
SCHEMBL13852931 0.89 RXFP1 (0.62) SCN8ASCN10ARXFP1
SCHEMBL20644107 0.89 SCN8A (0.62) SCN8ASCN10APNLIP
SCHEMBL20638950 0.86 SCN8A (0.64) SCN8ASCN10A
SCHEMBL20644197 0.86 SCN8A (0.64) SCN8ASCN10ARXFP1
SCHEMBL31297268 0.86 SCN8A (0.64) SCN8ASCN10ARXFP1
SCHEMBL31297293 0.86 SCN8A (0.64) SCN8ASCN10A
SCHEMBL20644023 0.84 SCN8A (0.66) SCN8ASCN10A
SCHEMBL30530104 0.84 KMT2A (0.53) SCN8ASCN10AMEN1KMT2AKCNK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2212290-B1 ARYL AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS VERTEX PHARMA (US) 2014-12-03 — — EP disclosed
US-8779197-B2 Aryl amides useful as inhibitors of voltage-gated sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-07-15 — — US disclosed
US-8779197-B2 Aryl amides useful as inhibitors of voltage-gated sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-07-15 — — US disclosed
US-8779197-B2 Aryl amides useful as inhibitors of voltage-gated sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-07-15 — — US disclosed
EP-2212290-A1 ARYL AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS Vertex Pharmaceuticals Incorporated (US) 2010-08-04 — — EP disclosed
US-20090118338-A1 ARYL AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2009-05-07 — — US disclosed
US-20090118338-A1 ARYL AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2009-05-07 — — US disclosed
US-20090118338-A1 ARYL AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2009-05-07 — — US disclosed
WO-2009049183-A1 ARYL AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-04-16 — — WO disclosed
WO-2009049183-A1 ARYL AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-04-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118338-A1 ARYL AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS KCNH2, KCNH3, SCN5A SCN8A 63/4885SCN10A 25/4885PNLIP 2224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback